case_images: PMC11790561_01
case_images: PET-CT imaging was performed at the time of initial diagnosis (A) and after two cycles of chemotherapy (B).
case_images: fonc-14-1480880-g001.jpg
case_images: PMC11790561_01_fonc-14-1480880-g001.jpg
case_images: f1
case_images: Positron emission tomography-computed tomography (PET-CT) showed multiple soft-tissue nodular shadows in the left supraclavicular and subclavian regions, with partial fusion into clumps ( Figure 1A ). A complete response (CR) was achieved on PET-CT evaluation ( Figure 1B ). On 30 November 2023, the "alectinib + VRCD" regimen was used for the third chemotherapy cycle.
case_images: H&E staining and immunohistochemistry analysis were performed on the tumor tissues. (A) H&E staining showed tumor cells with immunoblast/plasma-cell morphology. (B-E) Immunohistochemistry analysis revealed CD138 positivity (B), weak CD30 positivity (C), Bob.1 positivity (D), and Oct-2 positivity (E).
case_images: fonc-14-1480880-g002.jpg
case_images: PMC11790561_01_fonc-14-1480880-g002.jpg
case_images: f2
case_images: The pathological examination of the left cervical lymph node biopsy indicated ALK+ LBCL, namely lymphoid tissue hyperplasia, patchy diffuse infiltration, and the proliferation of morphologically abnormal cells with large volume, abundant cytoplasm, round or irregular nuclei, thin chromatin, and visible nucleoli ( Figure 2A ).